It was shown that in HCC cells, sorafenib increased necrosis, as demonstrated by the elevated counts of annexinV-negative/Pi-positive cells after 48 h of sorafenib treatment [27,41,85]. Here, ANXA5 is linked to hepatocellular carcinoma.